Fed Rate Cut Hopes Dim as Jobs Data Highlights Persistent CostofLiving Pressures UK Train Operators Face New Police Scoring System on Sexual Harassment Despite No Financial Penalties UK Government Proposes VAT Reduction for Theme Parks and Childrens Meals to Ease CostofLiving Burden US April Payrolls Surprise to the Upside But Economists Flag Underlying Concerns Government May Sell Up to 2 Stake in LIC Targeting Rs 10000 Crore in Divestment ADP April Private Payrolls Rise 109000 Exceeding Forecasts Fed Rate Cut Prospects Dim MESO Q1 2026 Earnings EPS Miss Amid Ongoing Pipeline Progress RMTI Q1 2026 Earnings EPS Misses Estimates Stock Declines on Weak Performance OXLC Q4 2025 Earnings EPS Misses Estimates as Net Investment Income Falls Short BCAB Q4 2025 Earnings NarrowerthanExpected Loss Drives Positive Stock Reaction Revolve Group Inc RVLV Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick Amid Quiet Revenue Picture Hercules Capital HTGC Rallies 209 as Stock Approaches Key Resistance Level TransCode Therapeutics RNAZ Surges 2 as Biotech Stock Tests Key Resistance at 655 Ideal Power Inc IPWR Surges Nearly 30 on Heavy Volume Key Levels in Focus US Global Investors GROW Edges Higher Navigating Support and Resistance Levels Champions Oncology CSBR Gains 159 as Stock Approaches Key Resistance Level Reddit Stock Declines Nearly 6 Following Metas Launch of Competing Forum App Gran Tierra Energy Inc GTE Q4 2025 Earnings Narrower Loss Amid Operational Discipline Gladstone Land Preferred Stock LANDO Holds Steady Near Support as Income Seekers Eye Yield Kairos Pharma Ltd KAPA Q1 2026 Earnings EPS Misses Estimates Amid Ongoing ClinicalStage Operations Arteris Inc AIP Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Investor Sentiment Gilat Satellite Networks Q1 2026 Earnings Stellar EPS Surprise of 341 Drives Stock Higher Lowes Q1 2026 Earnings EPS Tops Estimates Amid Challenging Housing Market INLX Q1 2026 Earnings Significant EPS Miss but Stock Rallies 586 CLNN Q1 2026 Earnings Narrowed Loss Beats Expectations Amid Ongoing Clinical Progress GPCR Q1 2026 Earnings EPS Beat Drives Modest Stock Gain as PreRevenue Biotech Advances Pipeline